| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 02/19/2004 | US20040033200 Modified FVII in treatment of ARDS |
| 02/19/2004 | DE10237423A1 Treating immunological (or related) diseases, e.g. inflammatory bowel disease, rheumatoid arthritis or psoriasis, comprises administration of 3-methylene-2-indolinone derivative or quinazoline compound |
| 02/19/2004 | DE10235624A1 New fused tetracyclic compounds, e.g. endiandric acid H obtained from the plant Beilschmieda fulva, are c-maf and NFAT inhibitors useful for treating allergy or asthma |
| 02/19/2004 | CA2497658A1 Chromone derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | CA2495518A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | CA2495516A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | CA2495502A1 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | CA2494942A1 Substituted benzimidazole compounds |
| 02/19/2004 | CA2494865A1 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | CA2494827A1 Cannabinoid receptor ligands |
| 02/19/2004 | CA2494298A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| 02/19/2004 | CA2494065A1 Pharmaceutical formulations comprising combinations of epinastine, pseudoephedrine and methylephedrine |
| 02/19/2004 | CA2494028A1 Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors |
| 02/19/2004 | CA2494026A1 Phosphodiesterase 4 inhibitors |
| 02/19/2004 | CA2493660A1 Process for preparing quinolin antibiotic intermediates |
| 02/19/2004 | CA2493625A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/19/2004 | CA2487399A1 Combination of anti-muscarinic agents and non-glucocorticoid steroids |
| 02/18/2004 | EP1389618A1 Pyrazolo 1,5-a]pyridines and medicines containing the same |
| 02/18/2004 | EP1389616A1 Novel benzylpiperidine compound |
| 02/18/2004 | EP1389206A2 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 02/18/2004 | EP1389200A1 Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors |
| 02/18/2004 | EP1389181A2 Antioxidant nitroxides and nitrones as therapeutic agents |
| 02/18/2004 | EP1389129A1 Methods of treating respiratory conditions |
| 02/18/2004 | EP1389120A2 Identifying parasitic fungi of the organism, and treatment thereof |
| 02/18/2004 | EP1389110A2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 02/18/2004 | EP1389108A2 Methods for selective immunomodulation using pimecrolimus |
| 02/18/2004 | EP1325001B1 Anticholinergic agents that can be used as medicaments and method for the production thereof |
| 02/18/2004 | EP1240261B1 Medicament delivery device with moisture resistant coating |
| 02/18/2004 | EP1233786B1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance for the preparation of a medicament |
| 02/18/2004 | EP1216248B1 Triazolopyrimidine derivatives |
| 02/18/2004 | EP1213281B1 Novel amide derivatives |
| 02/18/2004 | EP1196410B1 Respiratory syncytial virus replication inhibitors |
| 02/18/2004 | EP1183252B1 pharmaceutically active compounds |
| 02/18/2004 | EP1178958B1 N-cyanomethyl amides as protease inhibitors |
| 02/18/2004 | EP1133494B1 8-azabicyclo 3.2.1]oct-2-ene and -octane derivatives |
| 02/18/2004 | EP1104422B1 Phenyl xanthine derivatives |
| 02/18/2004 | EP1082293B1 Formoterol polymorphs |
| 02/18/2004 | EP1049691B1 Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative |
| 02/18/2004 | EP1032396B1 Sterilization of glucocorticosteroids |
| 02/18/2004 | EP0980351B1 Benzylamine and phenylethylamine derivatives, processes for preparing the same and their use as medicaments |
| 02/18/2004 | CN1476448A Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 02/18/2004 | CN1476447A Aminothiazoles and their use as adenosine receptor antagonists |
| 02/18/2004 | CN1476442A Pyridine derivatives with IKB-kinase (IKK-beta) INhibiting activity |
| 02/18/2004 | CN1476434A Novel compounds |
| 02/18/2004 | CN1476427A Phenoxyphenyl alkane sulfonates |
| 02/18/2004 | CN1476331A Method and preparations having effect agaist allergic symptoms |
| 02/18/2004 | CN1475571A Expression of recombination SARS virus gene in pleiomorphic Hansen yeast and its use |
| 02/18/2004 | CN1475265A Medicament box used for treating acute anhelation syndrome |
| 02/18/2004 | CN1475264A New use of qingkailing preparation in treating of acute anhelation syndrome |
| 02/18/2004 | CN1475250A Multiuse pure natural plant preparation |
| 02/18/2004 | CN1475238A Kexinkang capsule preparation (for treating cough) and its preparation process |
| 02/18/2004 | CN1475225A Use of Bacille Calmette-Guerin polysaccharide nucleic acid in the preparation of medicine for oral cavity local administration |
| 02/18/2004 | CN1475223A Compound preparation containing ribavirin and new decanoy acetaldehyde sodium and its preparation method |
| 02/18/2004 | CN1475214A Application of amyl ethyl quin ether hydrochloride |
| 02/18/2004 | CN1138546C Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine |
| 02/18/2004 | CN1138535C Pharmaceutical compositions contg. effervescent acid -base couple |
| 02/18/2004 | CN1138505C Anti-angiogenic compositions and method of use |
| 02/17/2004 | US6693118 E.G., 1-(2-(6,7-METHYLENEDIOXYNAPHTH-2-YL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE AND 1-2-(4-CYCLOHEXENYLPHENYL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6 -TETRAHYDROPYRIDINE; apoptosis inhibition; treatment of graft rejection or of acute or chronic rheumatoid arthritis |
| 02/17/2004 | US6693116 Adenosine receptor ligands |
| 02/17/2004 | US6693108 Pyrimidinyl-guanidine derivatives |
| 02/17/2004 | US6693102 Pyridine-substituted pyrazolopyridine derivatives |
| 02/17/2004 | US6693098 Carboxylic acid or tetrazole derivatives containing carbamate groups are useful for treating the conditions associated with the urinary tract, pain, inflammation, respiratory states, edema formation of hypotensive vascular diseases |
| 02/17/2004 | US6693096 Treatment of inflammation-associated disorders using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
| 02/17/2004 | US6692741 Treatment of acute lung injury and fibrosis with antagonists of β6-specific antibodies |
| 02/17/2004 | CA2252401C Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors |
| 02/12/2004 | WO2004013629A2 Screening for agents suitable for treatment of leukocyte associated inflammatory diseases |
| 02/12/2004 | WO2004013156A1 Polymorphis of a known thiophenecarboxylic acid dodecahydrocyclopenta (a) phenanthrenyl ester |
| 02/12/2004 | WO2004013153A2 Macrolide compounds endowed with antiinflammatory activity |
| 02/12/2004 | WO2004013146A1 Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
| 02/12/2004 | WO2004013144A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/12/2004 | WO2004013140A1 Pyrazole compositions useful as inhibitors of gsk-3 |
| 02/12/2004 | WO2004013138A2 Imidazo`1,2-a!pyridines |
| 02/12/2004 | WO2004013135A1 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| 02/12/2004 | WO2004013134A2 Compounds |
| 02/12/2004 | WO2004013125A1 Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway |
| 02/12/2004 | WO2004013109A1 Resorcinol derivative |
| 02/12/2004 | WO2004012763A1 Modulation of mesenchymal cells via iga-receptors |
| 02/12/2004 | WO2004012731A1 Pyrrolidine derivatives as tryptase inhibitors |
| 02/12/2004 | WO2004012686A2 Nitrosated and/or nitrosylated ursodeoxycholic acid compounds, compositions and methods of use |
| 02/12/2004 | WO2004012671A2 Substituted furo [2,3-b] pyridine derivatives |
| 02/12/2004 | WO2004012655A2 Anti-microbial compositions and methods of using same |
| 02/12/2004 | WO2004012653A2 Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof |
| 02/12/2004 | WO2004012651A2 Composition for heart disease, method to prepare same and uses thereof |
| 02/12/2004 | WO2003103604A3 Gamma lactams as prostaglandin agonists and use thereof |
| 02/12/2004 | WO2003097582A3 Synthesis of benzonitriles and benzimidates |
| 02/12/2004 | WO2003094957A3 Methods of therapy for inducing tolerance |
| 02/12/2004 | WO2003091414A3 Adipocyte complement related protein zacrp8 |
| 02/12/2004 | WO2003091259A8 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors |
| 02/12/2004 | WO2003087832A3 Diagnosis of carcinoma using raigi polypeptides |
| 02/12/2004 | WO2003079885A3 Inhalable sustained therapeutic formulations |
| 02/12/2004 | WO2003070968A3 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE (GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 02/12/2004 | WO2003070236A3 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 02/12/2004 | WO2003051346A3 Use of selective pde5 inhibitors for treating partial and global respiratory failure |
| 02/12/2004 | WO2003049723A3 Use of protease-activated receptor-2 inhibitor in the manifacture of a medicament for treating delayed hypersensitivity |
| 02/12/2004 | WO2003049702A3 Vanilloid receptor ligands and their use in treatments |
| 02/12/2004 | WO2003037916A3 Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 02/12/2004 | WO2003020700A3 SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF |
| 02/12/2004 | WO2003013424A3 Use of r-nsaid compounds for anti-hiv treatment |
| 02/12/2004 | WO2003010159A8 Piperidine derivatives as nmda receptor antagonists |
| 02/12/2004 | WO2003008365A3 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |